July 24, 2007 11:52 ET
CHICAGO, ILLINOIS--(Marketwire - July 24, 2007) - MonoGen, Inc. ("Corporation") (TSX:MOG) today announced that it submitted its PMA Supplement for the use of the MonoPrep Pap Test with the Digene hc2 HPV DNA Tests before the end of June as expected.
During preliminary review of this Supplement, the FDA has indicated a concern about a certain subset of data within the statistical analysis. The company is in communication with the FDA to assess the best course of action to address this matter.
Ted S. Geiselman, MonoGen's President and CEO commented, "We are pleased with the quality of the data in the submission and look forward to working with the FDA to address their concerns as part of the ongoing review process."
With operational headquarters in the United States (Greater Chicago area), MonoGen is a medical device company developing an integrated suite of fully automated devices (the SAVANT LABORATORY SYSTEM™) for anatomic and molecular pathology laboratories. The SAVANT LABORATORY SYSTEM™ is being designed to automate processes performed by clinical laboratories to reduce their costs, increase throughput, and improve the quality and consistency of results.
The common shares of the Corporation are listed for trading on the Toronto Stock Exchange under the trading symbol "MOG".
This press release contains statements that are forward-looking in nature. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements. Forward-looking statements are based on the Corporation's beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to the Corporation. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause the Corporation's actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to MonoGen's ability to raise additional capital, MonoGen's ability to execute its business plan while obtaining and maintaining at all times its various regulatory approvals, the performance of its strategic partners including the performance of Cardinal Health in the commercialization of the Corporation's products in the marketplace and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and the Corporation undertakes no obligation to update publicly or revise any forward looking information, whether as a result of new information, future events or otherwise.
MonoGen, Inc.Investor Relations847-758-4284847-439-9392 (FAX)email@example.com
See all RSS Newsfeeds